Ann Thorac Surg 1996;62:1472-1473
© 1996 The Society of Thoracic Surgeons
Discussion
Discussion
| The first 20% of the full text of this article appears below. |
See also page 1467.
DR R. MORTON BOLMAN III (Minneapolis, MN): Doctor Reichenspurner, I congratulate you on a really important study. Stanford has the longest experience in North America with lung transplantation and, I think, can give us data that really are not available anywhere else. For those of us involved in lung transplantation, this is a tremendously important and depressing problem. It seems as if every week at our conference we have new patients who have turned up with this diagnosis and it brings up a number of interesting ethical concerns.
First of all, could you tell me, in terms of treatment, do you base your treatment or decision to treat or not to treat at all on the histology? In other words, if there is an active lymphocytic infiltrate with the OB, are you more likely to treat with an antilymphocytic agent? If it has burned out and just turned into scar, do you think the treatment is less effective? Do you differentiate at all based on histology in terms of your decision to treat and your type of treatment?
DR REICHENSPURNER: Yes, I think it is very important to look at the histology very carefully. If there is any presence of a concurrent acute rejection, or . . . [Full Text of this Article]
Related Article
-
Stanford Experience With Obliterative Bronchiolitis After Lung and Heart-Lung Transplantation
- Hermann Reichenspurner, Reda E. Girgis, Robert C. Robbins, Kwok L. Yun, Michael Nitschke, Gerald J. Berry, Randall E. Morris, James Theodore, and Bruce A. Reitz
Ann. Thorac. Surg. 1996 62: 1467-1472.
[Abstract]
[Full Text]
Copyright © 1996 by The Society of Thoracic Surgeons.
